Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Ibrutinib Maintenance (I-M) Following Frontline Intensive Induction in Mantle Cell Lymphoma (MCL): Interim Safety, Response and Sequential MRD Evaluation

Reem Karmali, MD, Jeremy S. Abramson, MD MMSc, Deborah M. Stephens, DO, Jeffrey A. Barnes, MD PhD, Jason Kaplan, MD, Jane N. Winter, MD, Shuo Ma, MD PhD, Juehua Gao, MD PhD, Adam M. Petrich, MD, Ephraim Hochberg, MD, Ronald W. Takvorian, MD, Frank Kuhr, PhD, Valerie Nelson, MD MBA, Leo I. Gordon, MD, Barbara Pro, MD

Blood (2019) 134 (Supplement_1): 3990.

https://doi.org/10.1182/blood-2019-126920

Published: 2019

Journal Articles

A Phase II Study of Brentuximab Vedotin Plus Adriamycin and Dacarbazine without Radiation in Non-Bulky Limited Stage Classical Hodgkin Lymphoma

Jeremy S. Abramson, MD MMSc, Robert A. Redd, MS, Jeffrey A. Barnes, MD PhD, Elizabeth Bengtson, MD, Ronald W. Takvorian, MD, Lubomir Sokol, MD PhD, Frederick Lansigan, MD, Philippe Armand, MD PhD, Bijal D. Shah, MD, Eric D Jacobsen, MD, Donna S Neuberg, ScD, Ann S. LaCasce, MD MSc, Celeste M. Bello, MD

Blood (2018) 132 (Supplement 1): 1654.

https://doi.org/10.1182/blood-2018-99-115173

Published: 2018

Journal Articles

A Multicenter, Phase II Study of Ibrutinib Plus FCR (iFCR) As Frontline Therapy for Younger CLL Patients

Matthew S. Davids, MD, Haesook T Kim, PhD, Danielle M. Brander, MD, Jad Bsat, BA, Alexandra Savell, BS, Karen Francoeur, RN, Caron Jacobson, MD, Samuel Y. Ng, MDPhD, Ann S LaCasce, MD MSc, Ephraim P. Hochberg, MD, Ronald W. Takvorian, MD, Jeremy S. Abramson, MD MMSc, David C. Fisher, MD PhD, Jennifer R. Brown, MD PhD

Blood (2017) 130 (Supplement 1): 496.

https://doi.org/10.1182/blood.V130.Suppl_1.496.496

Published: 2017

Journal Articles

A Phase 2 Study of Fludarabine and Rituximab for the Treatment of Marginal Zone Lymphomas.

Jennifer R. Brown, MD, PhD, Jonathan Friedberg, MD, Yang Feng, MS, Kimberly Phillips, BA, Jennifer C. Clark, MA, Paola dal Cin, PhD, Robin Joyce, MD, David C. Fisher, MD, Richard I. Fisher, MD, Ronald W. Takvorian, MD, Jane Liesveld, MD, Diana Marquis, BS, Donna Neuberg, ScD, Arnold S. Freedman, MD

Blood (2007) 110 (11): 1358.

https://doi.org/10.1182/blood.V110.11.1358.1358

Published: 2007

Journal Articles

Prospective Evaluation of FDG-PET Imaging of Treatment Response in Relapsed Follicular Lymphoma.

Jennifer R. Brown, MD, PhD, Iryna Rastarhuyeva, MD, Jyothi Jagannathan, MD, Kristen Stevenson, MS, Donna Neuberg, ScD, Yulia Melenevsky, MD, Kimberly S. Phillips, BA, Jennifer C. Clark, MA, Ronald W. Takvorian, MD, David C. Fisher, MD, Arnold S. Freedman, MD, Annick D. Van den Abbeele, MD

Blood (2007) 110 (11): 2331.

https://doi.org/10.1182/blood.V110.11.2331.2331

Published: 2007

NARROW

Ibrutinib Maintenance (I-M) Following Frontline Intensive Induction in Mantle Cell Lymphoma (MCL): Interim Safety, Response and Sequential MRD Evaluation

A Phase II Study of Brentuximab Vedotin Plus Adriamycin and Dacarbazine without Radiation in Non-Bulky Limited Stage Classical Hodgkin Lymphoma

A Multicenter, Phase II Study of Ibrutinib Plus FCR (iFCR) As Frontline Therapy for Younger CLL Patients

A Phase 2 Study of Fludarabine and Rituximab for the Treatment of Marginal Zone Lymphomas.

Prospective Evaluation of FDG-PET Imaging of Treatment Response in Relapsed Follicular Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Ibrutinib Maintenance (I-M) Following Frontline Intensive Induction in Mantle Cell Lymphoma (MCL): Interim Safety, Response and Sequential MRD Evaluation

A Phase II Study of Brentuximab Vedotin Plus Adriamycin and Dacarbazine without Radiation in Non-Bulky Limited Stage Classical Hodgkin Lymphoma

A Multicenter, Phase II Study of Ibrutinib Plus FCR (iFCR) As Frontline Therapy for Younger CLL Patients

A Phase 2 Study of Fludarabine and Rituximab for the Treatment of Marginal Zone Lymphomas.

Prospective Evaluation of FDG-PET Imaging of Treatment Response in Relapsed Follicular Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only